HIV Drug Development Pipeline Update, Fall 2014 Edition

HIV Drug Development Pipeline Update, Fall 2014 Edition

1 of 10
Next >

Some might say that the golden age of HIV drug development has come and gone. Those people might just be right.

Some might say that the golden age of HIV drug development has come and gone. Those people might just be right.

But if there are fewer HIV antiretrovirals in the pipeline these days than there were in the late 1990s and much of the 2000s, it's with good reason: The drugs that made it through that grind transformed HIV treatment from a toxicity-filled, resistance-prone mountain of a pill burden into a highly manageable, tremendously effective intervention.

However, HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. At IDWeek 2014 in Philadelphia, Paul Sax, M.D., made the case for this new generation of drugs, and provided an update on several of the most noteworthy candidates currently in development.